The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ESH MM 2018 | MRD as a response assessment in elderly multiple myeloma
Measurable residual disease (MRD) is gaining traction as a tool for response assessment, prognosis and clinical decision making in the field of hem-onc; could it be particularly useful in the management of elderly multiple myeloma? We spoke to Alessandra Larocca, MD, PhD, of the University Hospital Città della Salute e della Scienza, Torino, Italy, on just that at the European School of Haematology (ESH) International Conference on Multiple Myeloma 2018, held in Mandelieu, France.
